Fig. 6
From: A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
E-RS™:COPD total score (full analysis set). Data are least squares means treatment–placebo differences and 95% confidence intervals. *p < 0.05; †p < 0.01 vs placebo. Least squares mean changes from baseline in the placebo group (N = 79) were 0.38, 0.57, 1.11 and 1.19 at Weeks 1, 2, 3 and 4, respectively. Abbreviation: ERS:COPD™, Evaluating Respiratory Symptoms in COPD questionnaire